BMEA logo

BMEA Biomea Fusion, Inc.

NASDAQ Global Select · Biotechnology · Healthcare

$0.57
-0.01 (-2.38%)

Biomea Fusion, Inc., a clinical-stage diabetes and obesity medicines company, focuses on the discovery and development of oral drugs to treat patients with diabetes and obesity. It’s lead clinical program’s drug candidates are COVALENT-111 and COVALENT-112, which has completed Phase II clinical trials of icovamenib for the treatment of Type 1 and Type 2 diabetes; COVALENT-211, which is in Phase II…

Market Cap: $41.75Mbiomeafusion.com

Price

No data yet.

Social Signal Score

51
5d
—
30d
50
1 mentions
—
60d
50
2 mentions
—
90d
53
6 mentions
—
news: 6

Analyst Ratings

14 analysts
Buyconsensus
Strong Buy 0Buy 11Hold 3Sell 0Strong Sell 0
Avg price target$20.2+3416.7%
Low $10Median $19High $40
Current Consensus

Revenue

$0.00
$0.00
Mar 2020Sep 2026

Analyst Estimates

FY2025
$-1.53
$-1.62–$-1.31
5 analysts
FY2026
$-0.63
$-0.65–$-0.62
4 analysts
FY2027
$-0.72
$-0.84–$-0.64
4 analysts

Consensus estimates, not results. Via Financial Modeling Prep.

Company Profile

CEO
Michael J. Hitchcock
Sector
Healthcare
Industry
Biotechnology
Employees
34
Beta
-0.30
Country
US
Piotroski score
0 / 9 (Weak)
Altman Z-score
-24.48
biomeafusion.com